Sunday, May 28

Vytrus prepares to list on the SME stock exchange

Vytrus Biotech, a Catalan biotechnology company that develops active ingredients for the cosmetics industry, is finalizing the procedures to go public. This was announced this Tuesday by the company, which plans to debut in the BME Growth, the SME stock market, in the coming months. In fact, it is only waiting for the stock operator to give the go-ahead for its incorporation into this alternative market.

To prepare to take this leap, the firm has closed a financing round of 2.4 million euros that has renewed part of its shareholding. Specifically, the background IUCT Empren divests from the company after 9 years in its capital and Zamit Capital becomes part of it. In turn, they repeat the ‘family office’ of Julia Perfumeries and the Catalan Institute of Finance (ICF).

All this, at a time when biotechnology continues to grow at double digits. Vytrus has just closed the 2021 financial year, increasing its turnover by 65% ​​to 2.8 million euros. This figure also means more than doubling the sales they had before the pandemic, and consolidating the growth path of the last 5 years.

Related news

“Our business is based on the development, production and marketing of active ingredients with high added value for the cosmetic and dermatological markets”, explains the co-founder and CEO of Vytrus, Albert Jané. “Thanks to our plant stem cell culture technology, we obtain high-quality, natural and sustainable products,” he adds. “We want going to market to help us continue developing the great benefits of our technology and to allow us to boost the company’s growth,” he concludes.

In short, with their IPO they hope to both obtain liquidity and establish a market valuation for the company for future operations as well as “increase their brand image, transparency and solvency”.